Inversely, Metformin, a clinical drug used for type 2 diabetes and previously shown to stimulate TAp63 expression5, induced the protein level of CCDC3, which was well correlated with the induction of TAp63 and one of its targets, Sirt1, in a time-dependent manner (Fig. 3c). Here, CCDC3 is linked to type 2 diabetes mellitus.